List of works - Ileana S Mauldin

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

scientific article published oln 16 November 2016

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites

scientific article

Cytokines and TLR agonists influence the expression of retention integrins CD49a, CD49b and CD103 by T cells.

scientific article published on 4 November 2015

Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma

scientific article published on 06 August 2018

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk

scientific article

Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity

scientific article published in January 2018

Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases

scientific article

Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures

Perivascular Adipose Tissue Harbors Atheroprotective IgM-Producing B Cells.

scientific article published on 22 September 2017

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine

scientific article published on 4 November 2015

TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling

TLR2/6 agonists and IFNγ synergize to induce melanoma cells to produce T-cell recruiting chemokines

scientific article published on 7 November 2013

TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10

scientific article

The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cells

scientific article

The tyrosine phosphatase SHP-1 dampens murine Th17 development

scientific article

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases

scientific article

Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival

scientific article

List of works by Ileana S Mauldin

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites

Cytokines and TLR agonists influence the expression of retention integrins CD49a, CD49b and CD103 by T cells.

Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk

Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity

Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases

Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures

Perivascular Adipose Tissue Harbors Atheroprotective IgM-Producing B Cells.

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine

TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling

TLR2/6 agonists and IFNγ synergize to induce melanoma cells to produce T-cell recruiting chemokines

TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10

The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cells

The tyrosine phosphatase SHP-1 dampens murine Th17 development

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases

Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival